Results 91 to 100 of about 107,669 (285)

Recent Advances in Clinical Research of Prophylactic Vaccines Against Tuberculosis

Vaccines
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is one of the leading infectious causes of adult mortality worldwide. The Bacillus Calmette–Guérin (BCG) vaccine is currently the only approved vaccine for TB prevention, but its protective ...
Buyun Xu, Mengjuan Yuan, Lisa Yang, Lan Huang, Jingxin Li, Zhongming Tan   +5 more
doaj   +1 more source

Emerging Challenges and Opportunities in Infectious Disease Epidemiology. [PDF]

, 2019
Much of the intellectual tradition of modern epidemiology stems from efforts to understand and combat chronic diseases persisting through the 20th century epidemiologic transition of countries such as the United States and United Kingdom.
Lewnard, Joseph A, Reingold, Arthur L
core  

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis [PDF]

, 2023
Haoting Zhan, Li Yang, Yongmei Liu, Haolong Li, Xiaomeng Li, Haibin Wang, Jinfeng Cao, Shuhui Kang, Xinru Guo, Erhei Dai, Yongzhe Li   +10 more
openalex   +1 more source

Lung organoids as a human system for Mycobacteria infection modeling and drug testing

The FEBS Journal, EarlyView.
Mycobacterial infections, including tuberculosis (TB) and infections by nontuberculous mycobacteria (NTM), are still public health issues. In 2023, TB caused 1.25 million deaths, while NTM remain a clinical challenge for patients with cystic fibrosis (CF).
Stephen Adonai Leon‐Icaza, Romain Vergé, Raoul Mazars, Laurence Berry, Céline Cougoule   +4 more
wiley   +1 more source

Vaccines for tuberculosis.

, 2013
AbstractThis chapter describes the existing vaccines against tuberculosis, the nature of the protective immune response to tuberculosis, and the target populations for a new tuberculosis vaccine. The preclinical animal testing and clinical evaluation of candidate vaccines, the potential approaches to the development of a new tuberculosis vaccine, and ...
openaire   +2 more sources

Organisation of Health Care During an Outbreak of Marburg Haemorrhagic Fever in the Democratic Republic of Congo, 1999. [PDF]

, 2004
Organising health care was one of the tasks of the International Scientific and Technical Committee during the 1998-1999 outbreak in Durba/Watsa, in the north-eastern province (Province Orientale), Democratic Republic of Congo.
Borchert, M, Colebunders, R, Kinuani, L, Libande, M, Mustin, J P, Muyembe-Tamfum, J J, Olinda, L A, Pirard, P, Sleurs, H, Tshioko, F, Tshomba, A   +10 more
core   +2 more sources

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Health in the sustainable development goals: ready for a paradigm shift? [PDF]

, 2015
The Millennium Development Goals (MDGs) galvanized attention, resources and accountability on a small number of health concerns of low- and middle-income countries with unprecedented results.
Buse, K, Hawkes, S
core   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Nanoparticles in the treatment of chronic lung diseases [PDF]

, 2019
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G, Cosnarovici, Maria, Negrean, Vasile, Orasan, Olga H, Para, Ioana, Perne, Mirela G, Popovici, Ionela, Ruta, Victoria M, Tarmure, Simina, Todea, Doina A   +9 more
core   +2 more sources